Family History of Breast Cancer Is Associated with Elevated Risk of Prostate Cancer: Evidence for Shared Genetic Risks

Adrián Calvo Chozas a, Behrang Mahjani b, c, Lars Rönnegård a, d

a Department of Information and Technology, Dalarna University, Falun, Sweden; b Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai, New York, NY, USA; c Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; d Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, Uppsala, Sweden

Keywords
Prostate cancer · Breast cancer · Heritability · Genetic correlation · MCMCglmm

Abstract
Introduction: Although breast and prostate cancers arise in different organs and are more frequent in the opposite sex, multiple studies have reported an association between their family history. Analysis of single nucleotide polymorphism data, based on distant relatives, has revealed a small positive genetic correlation between these cancers explained by common variants. The estimate of genetic correlation based on close relatives reveals the extent to which shared genetic risks are explained by both common and rare variants. This estimate is unknown for breast and prostate cancer. Method: We estimated the relative risks, heritability, and genetic correlation of breast cancer and prostate cancer based on the Minnesota Breast and Prostate Cancer Study, a family study of 141 families ascertained for breast cancer. Results: Heritability of breast cancer was 0.34 (95% credible interval: 0.23–0.49) and 0.65 (95% credible interval: 0.36–0.97) for prostate cancer, and the genetic correlation was 0.23. In terms of odds ratios, these values correspond to a 1.3 times higher odds of breast cancer among probands, given that the brother has prostate cancer. Conclusion: This study shows the inherent relation between prostate cancer and breast cancer; an incident of one in a family increases the risk of developing the other. The large difference between estimates of genetic correlation from distant and close relatives, if replicated, suggests that rare variants contribute to the shared genetic risk of breast and prostate cancer. However, the difference could stem from genotype-by-family effects shared between the two types of cancers.

Introduction

Breast cancer is the most common cancer among women. It can occur among women and men but is more common among women. The lifetime risk of a woman in the United States developing breast cancer is about 13% [1]. Prostate cancer is the most common cancer among men in the US [2]. The incidence rate of prostate cancer increases with age, reaching 1 in every 52 in males between the age of 50–59 years [3, 4].

It is believed that both genetic and environmental factors contribute to the risk of developing breast and prostate cancer.
cancer. The heritability of breast cancer is estimated to be 18–27% [5, 6], whereas the heritability of prostate cancer is around 42% [5]. Breast cancer and prostate cancer are multifactorial disorders, and among men, they are rarely reported in the same individual. However, there is growing evidence for family clustering of these two types of cancers. A meta-analysis of 18 studies demonstrated reliable evidence that the history of female breast cancer in first-degree relatives was associated with an increased risk of prostate cancer (relative risk 1.18; 95% CI, 1.12–1.25) [7]. In another study, men with familial breast cancer had a 21% higher risk of prostate cancer (95% CI, 1.10–1.34) [8]. In this study, the risk of prostate cancer was higher when there was a history of both prostate and breast cancers in the family. These studies suggest a shared genetic etiology between breast cancer and prostate cancer. The shared etiology between these cancers can be due to pleiotropy, i.e., a genetic variation that impacts the risk for two or more disorders, or genetic correlation. For an individual to be at increased genetic risk for two diseases, the pleiotropic variation must be aligned; that is to say, the disorders must be positively genetically correlated. Indeed, using genome-wide association study summary statistics of distant relatives was associated with an increased risk of prostate cancer using both close and distant relatives. The study was further extended by Grabrick et al. [14] (2003); the authors collected prostate cancer data in a subset of families of the original breast cancer study via questionnaires. The questionnaires were sent to men over 40 years, and 118 incidents of prostate cancer were found. Here, we will refer to this substudy as the Minnesota Breast and Prostate Cancer Study (MBPCS). The data have been used in several studies of breast and prostate cancer [12, 14–17]. The data include 141 families and are described in more detail in Table 1.

### Materials and Methods

#### Study Population

We used data from the Minnesota Breast and Prostate Cancer Study available in the kinship2 package [10] in R. The data were collected as follows. Between 1944 and 1952, a family study of breast cancer was initiated at the Dight Institute for Human Genetics at the University of Minnesota by Anderson and colleagues [11] (1960) to investigate whether relatives of breast cancer patients may see an increase in their risk of developing cancer. Sellers et al. [12] (1995) and Sellers et al. [13] (1999) performed a follow-up study to examine the heredity of breast cancer risk. Families were contacted to extend the number of relatives in the analysis [12, 13]. A total of 118 families were excluded, prior to the construction of the dataset, due to little or no information regarding relatives (for further details, see [13]). The subjects selected to be part of the study were the proband’s relatives.

#### Statistical Analysis

To investigate the co-inheritance of breast and prostate cancer, we used Fisher’s infinitesimal model which assumes that a large number of genes, each having a small effect, affects the probability of having breast and prostate cancer [18]. The binary outcome (response variable) was fitted using a linear mixed model under Gaussian assumptions and using the liability threshold model described below.

To estimate the heritability of a single phenotype (either breast cancer or prostate cancer), we used the following linear mixed model [18]:

$$Y = \mu + Zb + e$$

(Eq. 1)

where $Y$ is the $N$-vector of binary outcomes, $\mu$ is the intercept term, $Z$ is the $N \times q$ design matrix for estimating the genetic random effects for each individual, $q$ is the total number of individuals in the pedigree, $b$ is a $q$-vector of random genetic effects, and $e$ is a vector of residuals. The two vectors $b$ and $e$ are independent and multivariate normal with $b \sim N(0,Aq_\sigma)$ and $e \sim N(0,\sigma^2I)$, where $\sigma^2$ is the residual variance, $I$ is the identity matrix, $q_\sigma$ is the variance of the genetic effects, and $A$ is the relationship matrix [19], with the elements:

$$a_{ij} = \begin{cases} 1 & \\ 0.5 \times (a_{\text{mother of } i,j} + a_{\text{father of } i,j}) & \end{cases}$$

The narrow-sense heritability is $h^2 = q_\sigma^2/(\sigma^2 + \sigma_i^2)$, which affects how often cancer is inherited within families compared to between
families. For large \( h^2 \), individuals with cancer are clustered within families and cancer is found more frequently among close relatives.

**Bivariate Model for Breast and Prostate Cancer**

We used a bivariate linear mixed model to estimate the incidents of both breast and prostate cancer. The bivariate response variable \( Y_{bp} \) is of length \( 2N \) and is equal to \( (Y_b, Y_p) \), where \( Y_b \) is the vector of outcomes for breast cancer, and \( Y_p \) is the vector of outcomes for prostate cancer. Here, the vector of random genetic effects is \( b_{bp} \), that is twice as long as the random effect \( b \) in Eq. 1, and with residuals \( e_{bp}, b_{2p} \) and \( e_{tp} \) are assumed to be multivariate normally distributed with

\[
\begin{bmatrix}
    b_{bp} \\
    e_{tp}
\end{bmatrix}
\sim N\left(\begin{bmatrix}
    0 \\
    0
\end{bmatrix},
    \begin{bmatrix}
    G & 0 \\
    0 & R
\end{bmatrix}\right)
\]

(Eq. 2)

where \( G \) (size \( 2q \times 2q \)) and \( R \) (size \( 2N \times 2N \)) are the (co)variance matrices of the random effects and residuals, respectively. From Eq. 2, it can be noted that the residuals are assumed to be independent of the genetic effects; a standard assumption to enable estimation of variance components for both genetic effects and residuals in pedigree studies [20]. However, the genetic effects are allowed to be correlated between traits

\[
G = \begin{bmatrix}
\sigma^2_{b1} & \rho \sigma_{b1} \sigma_{b2} \\
\rho \sigma_{b1} \sigma_{b2} & \sigma^2_{b2}
\end{bmatrix}
\]

(Eq. 3)

and the residuals can also be correlated between traits

\[
R = \begin{bmatrix}
\sigma^2_e & \rho \sigma_e \sigma_s \\
\rho \sigma_e \sigma_s & \sigma^2_s
\end{bmatrix}
\]

(Eq. 4)

The genetic correlation \( \rho \) is a measure of how often breast cancer and prostate cancer are inherited together among relatives, whereas \( \sigma^2_{b1} \) and \( \sigma^2_s \) are the genetic variances for breast and prostate cancer, respectively. Furthermore, \( \sigma^2_e \) and \( \sigma^2_s \) are the residual variances for the two traits, and \( r \) is the correlation between the residuals of the two traits.

**Bayesian Inference Using MCMCglmm**

We used a Bayesian framework to estimate the variance components. Then, we calculated the mean of the posterior as the estimate of the variance components. We reported the results with 95% credible intervals (CrI), using Bayesian highest posterior density interval, which is analogous to two-sided 95% confidence intervals in frequentist statistics. We used the MCMCglmm package to fit the bivariate linear mixed model [21]. This package is suitable for the analysis because it can deal with large pedigree data, and it provides the estimates of the correlation parameters \( \rho \) and \( r \). The package uses Markov Chain Monte Carlo (MCMC) methods combined with Gibbs sampling, slice sampling, and Metropolis-Hastings updates. The prior for the intercept term is Gaussian, whereas inverse-Wishart priors are used for the variance and covariance parameters.

The bivariate model was fitted using 600,000 iterations in the MCMC algorithm. The MCMC sample size after thinning (every 1,000 iterations) and removing the burn-in period of 3,000 was 597. Thinning was set to a large value (1,000) to ensure an autocorrelation of less than 0.1 (for more details, see [22]). Four independent MCMC chains were run to assess the stability of the results.

**Liability Threshold Model**

The liability threshold model is the most common approach for analyzing binary phenotypes where each individual has a hypothetical continuous liability composed of latent genetic and environmental factors [23]. Using the liability threshold model, it is possible to analyze the data based on the Gaussian assumption and then transform the estimates to those expected from a binomial probit model in a generalized linear mixed model (GLMM). In other words, the liability threshold model is mathematically equivalent to a probit-like risk model [24, 25].

Let \( h^2_b \) be the heritability estimate obtained from the Gaussian linear mixed model with observed binary outcomes. The expected heritability on the underlying scale \( h^2_l \) under probit GLMM assumptions is (Fig. 1):

\[
h^2_l = h^2_b \frac{K (1 - K)}{z^2}
\]

(Eq. 5)
Association between Breast and Prostate Cancer

where $K$ is the proportion of cancer in the dataset, and $z$ is the height of the standard normal probability density function at the threshold cutoff point in the probit model. The genetic correlation $\rho$ is unaffected by the transformation from the observed to the underlying scale [26].

Calculations of Odds Ratios and Relative Risk for Pairs of Female-Male Relatives

The estimates of fixed effects (covariates) and random effects from the linear mixed model can be used to calculate odds ratios and relative risks. Given these parameters, the underlying bivariate normal distribution (of having breast/prostate cancer) for pairs of related male-female individuals is known. The correlation of this bivariate distribution is $c\rho h_{l,bc}h_{l,pc}$, where $c$ is the coefficient of relationship, $\rho$ is the genetic correlation, $h_{l,bc}$ is the square root of the heritability of breast cancer on the underlying liability scale, and $h_{l,pc}$ is the square root of the heritability of prostate cancer on the underlying liability scale. Furthermore, the underlying bivariate normal distribution has unit marginal variances (following the assumptions of the probit model), and the two means in the bivariate distribution are given by the cancer proportions in the population.

We estimated the following four probabilities by calculating the proportion of the density distribution in the four quadrants of a two-dimensional coordinate system (Fig. 2):

- $P_0 = P(\text{neither breast nor prostate cancer})$,
- $P_{12} = P(\text{both breast and prostate cancer})$,
- $P_1 = P(\text{breast cancer but no prostate cancer})$,
- $P_2 = P(\text{no breast cancer but prostate cancer})$.

The odds ratio of getting cancer given the relative’s status is

$$\text{OR} = \frac{P_0 \times P_{12}}{P_1 \times P_2} \quad \text{(Eq. 6)}$$

and the relative risk of breast cancer given the status of the male relative is

$$\text{RR}_{bc} = \frac{P_0 / (P_0 + P_1)}{P_2 / (P_2 + P_{12})} \quad \text{(Eq. 7)}$$

and the relative risk of prostate cancer given the status of the female relative is

$$\text{RR}_{pc} = \frac{P_0 / (P_0 + P_2)}{P_1 / (P_1 + P_{12})} \quad \text{(Eq. 8)}$$

The R code for the bivariate model, computing the odds ratios, and the relative risks are available at our GitHub repository: https://github.com/Adrcalvo/Genetic_correlation_between_breast_and_prostate_cancer.

Results

The cohort contained 141 families with 11,474 individuals, of which 126 (1.10%) were diagnosed with prostate cancer, and 495 (4.31%) were diagnosed with breast cancer. There were 1,147 (10%) individuals with a miss-
ing value for sex. Families contained information for individuals up to five generations. Table 1 describes the characteristics of different family types.

The bivariate linear mixed model was fitted to the MBPCS data. Detailed results with trace plots of the MCMC chain are presented in online supplementary material 1 (see www.karger.com/doi/10.1159/000521215 for all online suppl. material). Results for univariate analyses of prostate and breast cancer cases are presented in online supplementary material 2, showing that similar heritability estimates were obtained from the univariate analyses.

The estimate of the heritability (posterior means) for breast cancer and prostate cancer on the observed scale was 0.095 and 0.031, respectively. The 95% CrI for breast and prostate cancer cases on the observed scale was (95% CrI, 0.085–0.106) and (95% CrI, 0.024–0.037), respectively. In the liability scale, we estimated heritability of 0.34 (95% CrI, 0.23–0.49) for breast cancer and 0.65 (95% CrI, 0.36–0.97) for prostate cancer. In summary, the estimated heritability was more than three times as large for breast cancer compared to prostate cancer on the observed scale, whereas the estimates on the liability scale were almost twice as large for prostate cancer compared to breast cancer. The reason for this discrepancy is that the observed scale is highly affected by the incidence rate of the two types of cancers, whereas this is corrected for on the liability scale (see Eq. 5). The estimates on the liability scale (breast cancer 0.34; prostate cancer 0.65) are, therefore, the ones reflecting the true narrow-sense heritability for the two traits.

We observed a genetic covariance of 0.0014 (95% CrI, −0.0004 to 0.0034) corresponding to a genetic correlation of 0.23. Over 95% of the sampled posterior distribution was greater than zero for the genetic covariance (Fig. 3). Therefore, we observed reliable evidence that there was a positive genetic correlation between the two cancers.

### Odds Ratios and Relative Risks for Pairs of Relatives

We estimated the probability of developing breast and prostate cancer for a female-male pair of individuals from the underlying bivariate distribution. The underlying distribution and the observed proportions are shown in Figure 2 for male-female relatives with a coefficient of relationship 0.5 (full siblings).

These probabilities depend on the two estimated heritabilities and the genetic correlation. Consequently, these estimated values can be summarized in terms of odds ratios and relative risks, which are easier to interpret in practice. We observed a higher odds ratio for the closer relative (Table 2). For instance, females with a full sibling brother (coefficients of relationship = 0.5) with prostate cancer had an odds ratio of 1.276 for getting breast cancer. For a female with a male cousin (coefficients of relationship = 0.125) with prostate cancer, the odds ratio of getting breast cancer was 1.06. The credibility interval of the odds ratio was a direct function of the credibility interval of the heritability estimate but was not feasible to compute since it depends on a bivariate integral.

### Discussion

In this study, we investigated the association between prostate cancer and breast cancer using MBPCS data. We observed 1.28 times higher odds of breast cancer among probands with a brother with prostate cancer. Using multivariate GLMM and under the liability threshold assumption, we estimated 65% (95% CrI, 36–97%) and 34% (95% CrI, 23–49%) of the variance in risk of prostate cancer and breast cancer, respectively, were due to direct additive genetics (narrow-sense heritability). Other studies

| Coefficient of relationship | OR$^1$ | Relative risk |
|----------------------------|-------|--------------|
| 0.5 (full siblings)        | 1.276 | 1.008        |
| 0.25 (half siblings)       | 1.131 | 1.004        |
| 0.125 (cousins)            | 1.064 | 1.002        |

1 The computations of OR are symmetric (Eq. 6) and, consequently, the OR of a male getting prostate cancer given that a female relative has breast cancer is the same as the odds ratio of a female getting breast cancer given that a male relative has prostate cancer. OR, odds ratio.
reported a similar estimate ofheritabilities. In particular, a large Nordic study by Lichtenstein et al. [5] reported 57% heritability for breast cancer and 31% for prostate cancer [7].

We observed reliable evidence for a genetic correlation of 0.23 between the two types of cancers. The analysis gives strong evidence for a large positive genetic correlation between the two types of cancers because over 95% of the sampled posterior distribution was greater than zero for the genetic covariance (Fig. 3). Our estimate of the genetic correlation, using family-based data, was three-fold higher than the previously estimated SNP-based genetic correlation (0.21 vs. 0.072) [9]. The difference in these estimates suggests that rare variants contribute to the shared genetic risk of breast and prostate cancer. However, this statement should be interpreted with caution since the SNP-based genetic correlation may differ from family-based genetic correlation due to other factors (e.g., genotype-by-family effects shared between the two types of cancers).

Rare variants, in particular protein-truncating variants (PTVs), tend to have larger effect sizes and dramatically change gene expression and function. Studies have shown that rare PTVs, in general, are more damaging than common PTVs. For example, for breast cancer, findings suggest that rare and common breast cancer susceptibility loci are differentially associated with tumor characteristics and survival [27]. Similarly, for prostate cancer, a differential burden of rare variants is identified between metastatic and nonaggressive cases [28]. Due to higher genetic correlations among relatives, it is more likely that rare damaging variants linked to breast cancer are observed in an individual if someone in the family has been affected with breast cancer. And due to the genetic correlation between breast and prostate cancer, then, it is more likely that rare damaging variants linked to breast cancer are observed in an individual if someone in the family has been affected with prostate cancer. The same argument is valid for prostate cancer.

Understanding the genetic correlation between prostate and breast cancer will eventually pave the way towards a better understanding of the causality relationships between these two types of cancers. We also presented an interpretation of the estimated heritabilities and genetic correlation in terms of odds ratios and relative risk, which we hope will be useful as guidelines for applied researchers and practitioners (Table 2). We observed that the odds of developing breast cancer was increased by 28%, 13%, and 6% if a brother, half-sibling, or cousin had prostate cancer, respectively.

Polygenic risk scores aggregate the effects of many genetic variants across the human genome and have been proposed as a tool of clinical medicine to measure a person’s genetic risk of a certain disorder. However, polygenic risk scores are still not ready for clinical use and further research is needed in this area. A recent study reported that the information of relatives would substantially increase the efficiency of genetic prediction [29].

The current study has several strengths. Although relative risk and heritability of breast and prostate cancer were estimated in previous studies based on both family-based and SNP-based data (distant relatives), to the best of our knowledge, genetic correlation has previously only been estimated based on SNP-based data (distant relatives). For the first time, we report the family-based estimation of the genetic correlation. Another strength of this work is the use of robust statistical methodologies to estimate heritability and genetic correlation. Different approaches to estimating the heritability of disease with dichotomous variables have been suggested [30]. The most common approach in human genetics, Falconer’s method, is based on comparing the tetrachoric correlations from relatives to a random sample from the general population. We used GLMM, which is a more flexible model and can treat complex pedigrees of variable size and structure to estimate the heritabilities and the genetic correlations of multiple traits [29].

The results of this study should be interpreted in the context of some limitations. First, the data are likely right-censored (some individuals may have received a diagnosis after study follow-up, and, therefore, these diagnoses would be missing from the data), in particular for individuals born in the later years of the study. Right-censored data could contribute to underdiagnoses of breast and prostate cancer and decreases the observed prevalence. Second, the individuals in the first generation might, to some degree, be selected based on cancer prevalence within families, which would, in that case, decrease the genetic variation among these individuals and bias our heritability estimates downwards. However, the bias is likely to be small since the selection of first-generation individuals was not very strong. Thirdly, this study lacks an analysis of environmental and lifestyle risk factors. Future studies with larger samples will be critical to elucidate further the role of genetics and environmental factors in the risk of prostate and breast cancer.
Conclusion

This study shed light on the association between prostate cancer and breast cancer; an incident of breast or prostate cancer in a family increases the risk of developing the other. The findings underline the importance of shared genetic variation as a risk factor for breast and prostate cancer and the importance of heritability-based analysis to understand their etiology. Therefore, it is important to ask patients—men and women—about the history of both breast cancer and prostate cancer in the family. These findings have translational relevance for cancer risk prediction in men and women. Patients with a high risk of developing cancer should be monitored more frequently, thereby increasing the likelihood of early detection.

Statement of Ethics

The data were publicly available and did not require ethical approval.

Conflict of Interest Statement

The authors do not have any conflict of interest to declare.

Funding Sources

No funding was used for this study.

Author Contributions

L.R. and A.C.C. designed the study and performed the data analysis. All authors contributed to writing the manuscript, study conception, interpretation of data, and critical revision of the manuscript for important intellectual content.

Data Availability Statement

The data are publicly available via GitHub: https://rdrr.io/github/mayoiverse/kinship2/man/minnbreast.html.

References

1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017; racial disparity in mortality by state. CA Cancer J Clin. 2017 Nov;67(6):439–48.
2. Mucci LA, Wilson KM, Giovannucci EL. Epidemiology of prostate cancer. Pathology and epidemiology of cancer. Cham: Springer International Publishing; 2017. p. 107–25.
3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr;144(8):1941–53.
4. Perdana NR, Mochtar CA, Umbas R, Hamid AR. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones. 2016 Jul;48(3):228–38.
5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000 Jul;343(2):78.
6. Liyquist J, Ruddy KJ, Vachon CM, Couch FJ. Common genetic variation and breast cancer risk: past, present, and future. Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):380–94.
7. Ren ZJ, Cao DH, Zhang Q, Ren PW, Liu LR, Wei Q, et al. First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis. BMC Cancer. 2019 Dec;19(1):871.
8. Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family history of breast or prostate cancer and prostate cancer risk. Clin Cancer Res. 2018 Dec;24(23):5910–7.
9. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyer JP, Han Y, et al. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Jan;10(1):431.
10. Sinnwell JP, Therneau TM, Schaid DJ. The kinship2 R package for pedigree data. Hum Hered. 2014 Jul;78(2):91–3.
11. Dorn HF, Anderson VE, Goodman HO, Reed SC. Variables related to human breast cancer. J Am Stat Assoc. 1960 Sep;55(291):586.
12. Perdrina NR, Moctar CA, Umbas R, Hamid AR. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones. 2016 Jul;48(3):228–38.
13. Lynch M, Walsh B. Genetics and analysis of quantitative traits, 1st ed. Sinauer Associates; 1997.
14. Hadfield J. Markov chain Monte Carlo generalised linear mixed models: course notes. 2019.
15. Vachon CM, Cerhan JR, Vierkant RA, Sellers TA. Investigation of an interaction of alcohol intake and family history on breast cancer risk in the Minnesota breast cancer family study. Cancer. 2001 Jul;52(2):240–8.
16. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000 Oct;284(14):1791–8.
17. Tseng M, Sellers TA, Vierkant RA, Kushih, Vachon CM. Mediterranean diet and breast density in the Minnesota breast cancer family study. Nutr Cancer. 2008;60(6):703–9.
18. Fisher RA. The correlation between relatives on the supposition of mendelian inheritance. Trans R Soc Edinburgh. 1918;52:399–433.
19. Pawitan Y. All likelihood: statistical modeling and inference using likelihood. 1st ed. OUP Oxford; 2013. p. 543.
20. Lynch M, Walsh B. Genetics and analysis of quantitative traits, 1st ed. Sinauer Associates; 1997.
21. Hadfield J. Markov chain Monte Carlo generalised linear mixed models: course notes. 2019.
22. Hadfield JD. MCMC methods for multi-response generalized linear mixed models: the MCMCglmm R Package. J Stat Soft. 2010; 33(2).
23. Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence among relatives. Ann Human Genet. 1965; 29(1):51–76.
24 Curnow RN. The multifactorial model for the inheritance of liability to disease and its implications for relatives at risk. *Biometrics*. 1972 Dec;28(4):931–46.
25 Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet*. 2011 Mar 11;88(3):294–305.
26 Lee SH, Yang J, Goddard ME, Visscher PM, Wray NR. Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. *Bioinformatics*. 2012 Oct;28(19):2540–2.
27 Li J, Ugalde-Morales E, Wen WX, Decker B, Eriksson M, Torstensson A, et al. Differential burden of rare and common variants on tumor characteristics, survival, and mode of detection in breast cancer. *Cancer Res*. 2018; 78(21):6329–38.
28 Mijuskovic M, Saunders EJ, Leongamornlert DA, Wakerell S, Whitmore I, Dadaev T, et al. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. *Br J Cancer*. 2018;119(1):96–104.
29 Truong B, Zhou X, Shin J, Li J, van der Werf JHJ, Le TD, et al. Efficient polygenic risk scores for biobank scale data by exploiting phenotypes from inferred relatives. *Nat Commun*. 2020;11(1):3074.
30 Tenesa A, Haley CS. The heritability of human disease: estimation, uses and abuses. *Nat Rev Genet*. 2013 Feb;14(2):139–49.